synthetic antirheumatic drug (csARD). The NSAID-sparing potential of etanercept was demonstrated in a recent trial In adults with stable AS receiving treatment with a biologic, we conditionally recommend against discontinuation of the biologic (new, PICO 66). In adults with stable AS receiving treatment with a biologic, we conditionally recommend against tapering of the biologic dose as a standard approach (new, PICO 65). Data from several observational studies suggest that discontinuation of